Observational - Potentially Actionable Mutations in Archived Non-Rhabdomyosarcoma Soft Tissue Sarcomas (NRSTS)
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Childhood Alveolar Soft-part Sarcoma
- Sponsor
- Children's Oncology Group
- Enrollment
- 70
- Locations
- 1
- Primary Endpoint
- Genetic changes that are most common and likely to have the greatest therapeutic impact
- Status
- Completed
- Last Updated
- 9 years ago
Overview
Brief Summary
This research trial studies genes in tissue samples from younger and adolescent patients with soft tissue sarcomas. Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors find better ways to treat cancer
Detailed Description
Study Subtype: Ancillary/Correlative Observational Study Model: Cohort Time Perspective: Retrospective Biospecimen Retention: Samples With DNA Biospecimen Description: Tissue Study Population Description: Existing NRSTS samples from the COG D9902/ARST0332 studies Sampling Method: Non-Probability Sample OBJECTIVES: I. To determine the frequency with which actionable mutations are found in archived non-rhabdomyosarcoma soft tissue sarcoma (NRSTS) tumor specimens using mass spectrometry (MS) analysis of tumor-derived deoxyribonucleic acid (DNA). OUTLINE: Archived DNA tissue samples are analyzed for frequency of genetic mutations, including single nucleotide polymorphisms (SNPs), single nucleotide variants (SNVs), and small deletions and/or insertions, by polymerase chain reaction (PCR) and mass spectometry (Sequenom MassARRAY). Results are then analyzed to determine whether specific mutations correlate with patient or disease features such as tumor stage, histological grade, or outcome.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Archived non-rhabdomyosarcoma soft tissue sarcoma (NRSTS) tumor-derived DNA
- •Synovial sarcoma, malignant peripheral nerve sheath tumor (MPNST), soft tissue sarcoma not otherwise specified (NOS), or other less common pediatric NRSTS
- •Formalin-fixed, paraffin-embedded (FFPE) tissue from patients enrolled on:
- •COG-D9902 Soft Tissue Sarcoma (STS) Biology and Banking Protocol
- •COG-ARST0332 A Risk-Based Treatment for Pediatric NRSTS Study
- •See Disease Characteristics
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Genetic changes that are most common and likely to have the greatest therapeutic impact
Time Frame: Up to 1 month
Frequency of individual mutated genes in patients with NRSTS
Time Frame: Up to 1 month